SUN Pharmaceutical Industries Limited — Exemestane Exporter Profile
Indian Pharmaceutical Exporter · #3 for Exemestane · $900.0K export value · DGFT Verified
SUN Pharmaceutical Industries Limited is the #3 Indian exporter of Exemestane with $900.0K in export value and 18 verified shipments. SUN Pharmaceutical Industries Limited holds a 6.2% market share in Exemestane exports across 4 countries. The company exports 118 pharmaceutical products worth $979.8M across 25 therapeutic categories.
SUN Pharmaceutical Industries Limited — Exemestane Export Profile: Buyers & Destinations
Where Does SUN Pharmaceutical Industries Limited Export Exemestane?
| Country | Value | Shipments | Share |
|---|---|---|---|
| BRAZIL | $483.9K | 14 | 73.2% |
| PERU | $68.4K | 2 | 10.3% |
| MEXICO | $58.7K | 2 | 8.9% |
| PHILIPPINES | $50.0K | 1 | 7.6% |
SUN Pharmaceutical Industries Limited exports Exemestane to 4 countries. The largest destination is BRAZIL accounting for 73.2% of SUN Pharmaceutical Industries Limited's Exemestane shipments, followed by PERU (10.3%) and MEXICO (8.9%). These destinations reflect SUN Pharmaceutical Industries Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Exemestane from SUN Pharmaceutical Industries Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| M/S. SUN FARMACEUTICA DO BRAZIL LTD | BRAZIL | $102.3K | 4 |
| SUN FARMACUTICA DO BRASIL LTDA, | BRAZIL | $90.6K | 2 |
| GRADINTER S.C | MEXICO | $58.7K | 2 |
| SUN FARMACUTICA DO BRASIL LTDA | BRAZIL | $50.0K | 1 |
| SUN FARMACEUTICA DO BRASIL LTD | BRAZIL | $50.0K | 1 |
| SUN FARMACEUTICA DO BRAZIL LIMITEDA | BRAZIL | $50.0K | 1 |
| MS SUN FARMACEUTICA DO BRAZIL LIMITED | BRAZIL | $50.0K | 1 |
| SUN FARMACEUTICA DO BRASIL LIMITED | BRAZIL | $50.0K | 1 |
| SUN PHARMA PHILIPPINES INC | PHILIPPINES | $50.0K | 1 |
| SUN PHARMACEUTICAL INDUSTRIES SAC | PERU | $43.3K | 1 |
SUN Pharmaceutical Industries Limited supplies Exemestane to 13 buyers globally. The largest buyer is M/S. SUN FARMACEUTICA DO BRAZIL LTD (BRAZIL), followed by SUN FARMACUTICA DO BRASIL LTDA, (BRAZIL) and GRADINTER S.C (MEXICO). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Exemestane Export Value and How Much Does SUN Pharmaceutical Industries Limited Contribute?
India exported $10.9M worth of Exemestane through 1,533 shipments from 87 suppliers to 57 countries, serving 196 buyers globally. SUN Pharmaceutical Industries Limited contributes $900.0K to this total, accounting for 6.2% of India's Exemestane exports. SUN Pharmaceutical Industries Limited ships Exemestane to 4 countries through 13 buyers.
What Is the Average Shipment Value for SUN Pharmaceutical Industries Limited's Exemestane Exports?
SUN Pharmaceutical Industries Limited's average Exemestane shipment value is $50.0K per consignment, based on 18 shipments totaling $900.0K. The largest destination is BRAZIL (73.2% of SUN Pharmaceutical Industries Limited's Exemestane exports).
How Does SUN Pharmaceutical Industries Limited Compare to Other Indian Exemestane Exporters?
SUN Pharmaceutical Industries Limited ranks #3 among 87 Indian Exemestane exporters with a 6.2% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($4.5M), MSN LABORATORIES PRIVATE LIMITED ($1.7M), EUGIA PHARMA SPECIALITIES LIMITED ($1.4M). SUN Pharmaceutical Industries Limited processed 18 shipments to 4 destination countries.
What Exemestane Formulations Does SUN Pharmaceutical Industries Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| EXEMESTANE TAB 25MG 9X10B MX PACK : 09*1 | $50.0K | 1 |
| EXEMESTANE TABLETS 25MG (EXEMESTANE) BN- | $50.0K | 1 |
| EXEMESTANE TABLETS 25MG (EXEMESTANE),BAT | $50.0K | 1 |
| EXEMESTANE TAB 25MG 3x10b BR PACK:03x10 | $50.0K | 1 |
| EMAH 25MG TABLETS EXEMESTANE PACK : 03*10 Batch No. As Per DOCUMENT | $50.0K | 1 |
| EXEMESTANE TABLETS 25MG EXEMESTANE PACK:03*10 BATCH:HAE2141A HAE2142A | $50.0K | 1 |
| EXEMESTANE TABLETS 25MG EXEMESTANE PACK:3x10 | $50.0K | 1 |
| EXEMESTANE TABLETS 25MG(EXEMESTANE)PACK:03*10 BATCH:HAE1786A,HAE3014APCS | $50.0K | 1 |
| EXMASIN TABLETS 25MG (EXEMESTANE TABLETS25MG) [8820 PACK X 14'S] | $50.0K | 1 |
| EXETANE TABS 25MG 03X10S EXEMESTANE TABLETS USP 25 MG ACT. QTY. 5976PACK X 3X 10 | $43.3K | 1 |
SUN Pharmaceutical Industries Limited exports 19 distinct Exemestane formulations including tablets, capsules, syrups, and combination drugs. The top formulation is EXEMESTANE TAB 25MG 9X10B MX PACK : 09*1 with 1 shipments worth $50.0K.
Regulatory Requirements: Exporting Exemestane to Key Markets
What SUN Pharmaceutical Industries Limited must comply with to export Exemestane to its top destination countries
Brazil — ANVISA
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Mexico — COFEPRIS
Approval Process
Generic registration under Mexican health law. NOM standards apply.
Timeline: 12–18 months
GMP & Export Requirements
Mexican GMP (NOM-059-SSA1); COFEPRIS overseas inspection or PIC/S certificate
Sanitary Import Permit from COFEPRIS; import licence via SAT
Note: COFEPRIS participates in PIC/S, easing recognition of PIC/S certificates from Indian authorities.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does SUN Pharmaceutical Industries Limited Compare to Nearest Exemestane Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 4 | MSN LABORATORIES PRIVATE LIMITED | $1.7M | 34 | 1 | $50.0K |
| 2 | EUGIA PHARMA SPECIALITIES LIMITED | $1.4M | 27 | 1 | $50.0K |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED ★ | $900.0K | 18 | 4 | $50.0K |
| 5 | CIPLA LIMITED | $800.0K | 16 | 3 | $50.0K |
| 6 | TITAN LABORATORIES PRIVATE LIMITED | $500.0K | 10 | 1 | $50.0K |
SUN Pharmaceutical Industries Limited ranks #3 among 87 Indian Exemestane exporters. Average shipment value of $50.0K compared to the market average of $124.9K. The closest competitors by value are MSN LABORATORIES PRIVATE LIMITED and EUGIA PHARMA SPECIALITIES LIMITED.
Which Indian Ports Ship Exemestane Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 314 | 20.5% |
| DELHI AIR CARGO ACC (INDEL4) | 273 | 17.8% |
| SAHAR AIR | 256 | 16.7% |
| DELHI AIR | 128 | 8.3% |
| Bombay Air Cargo | 62 | 4.0% |
| MUNDRA SEA (INMUN1) | 52 | 3.4% |
| MUNDRA SEA | 51 | 3.3% |
| AHEMDABAD AIR ACC (INAMD4) | 50 | 3.3% |
Geopolitical & Trade Policy Impact on SUN Pharmaceutical Industries Limited's Exemestane Exports
Sun Pharma's export operations, valued at $979.8 million, are significantly influenced by current geopolitical events. The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, a critical corridor for Indian pharmaceutical exports to Europe and North Africa. Major shipping lines have imposed 'Emergency Risk Surcharges,' increasing freight costs and extending transit times by 10–15 days. These delays pose risks to the integrity of time-sensitive and temperature-controlled pharmaceutical shipments. (pharmaceuticalcommerce.com)
In the United States, policy shifts towards domestic manufacturing and the imposition of tariffs on imported pharmaceuticals have created challenges for Indian exporters. Sun Pharma, which supplies a substantial portion of generics to the U.S. market, faces potential reductions in export volumes due to these protectionist measures. The company is exploring strategies such as establishing local partnerships and investing in U.S.-based manufacturing to mitigate these impacts. (odrindia.in)
The European Union's implementation of the Carbon Border Adjustment Mechanism (CBAM) introduces additional compliance requirements for exporters. Sun Pharma must adapt to these regulations to maintain its market presence in the EU, necessitating investments in sustainable manufacturing practices and comprehensive reporting mechanisms. (sgeexport.com)
SUN Pharmaceutical Industries Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains a critical focus for Sun Pharma. The company has encountered challenges with the U.S. FDA, including import alerts and non-compliance letters for certain facilities. Addressing these issues involves implementing corrective actions and awaiting reinspection to resume full operations. (business-standard.com)
Globally, the pharmaceutical industry faces increasing scrutiny regarding quality standards. Sun Pharma's commitment to adhering to Good Manufacturing Practices (GMP) and other regulatory requirements is essential to maintain its export licenses and market reputation. Continuous investment in quality control systems and compliance infrastructure is imperative to navigate the evolving regulatory landscape.
About SUN Pharmaceutical Industries Limited
SUN Pharmaceutical Industries Limited exports 118 products worth $979.8M. Beyond Exemestane, top products include Strip, Esomeprazole, Magnesium, Calcium, Omeprazole. View the complete SUN Pharmaceutical Industries Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Exemestane — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Exemestane shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: SUN Pharmaceutical Industries Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 19 individual customs records matching SUN Pharmaceutical Industries Limited exporting Exemestane, covering 19 formulations to 4 countries via 13 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 57+ countries, 196+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Exemestane Export Data from SUN Pharmaceutical Industries Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for SUN Pharmaceutical Industries Limited's Exemestane exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
SUN Pharmaceutical Industries Limited
Full Company Profile →
118 products · $979.8M total trade · 25 categories
Exemestane Stats
Company Overview
Top Products by SUN Pharmaceutical Industries Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for SUN Pharmaceutical Industries Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Exemestane. For current shipment-level data, contact TransData Nexus.